UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

October 24, 2007
(Date of report)
 
CARACO PHARMACEUTICAL LABORATORIES, LTD.
(Exact name of registrant as specified in its charter)

   
   

Michigan

  

0-24676

  

38-2505723

(State or other jurisdiction
of incorporation)

  

(Commission file number)

  

(I.R.S. employer
identification no.)
 
1150 Elijah McCoy Drive, Detroit, Michigan 48202
(Address of principal executive offices)
 
(313) 871-8400
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former name or former address, if changed since last report)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

   
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 140.14a-12)
   
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 2.02.  Results of Operations and Financial Condition

                On October 24, 2007, registrant announced its results of operations for the second quarter and first six months of fiscal 2008, as set forth in the press release included as Exhibit 99.1 hereto, which is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits

c)             Exhibits.

Exhibit No.             Description

99.1         Press Release of Caraco Pharmaceutical Laboratories, Ltd., dated October 24, 2007 announcing its results of operations for the second quarter and first six months of fiscal 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CARACO PHARMACEUTICAL LABORATORIES, LTD.

                 

Date:    October 24, 2007 By:  /s/ Daniel H. Movens
   
    Daniel H. Movens
    Chief Executive Officer


Exhibit Index

 
99.1

2